Equities

CSMED

DK0061668225

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.657 ^DKK	-2.35%		+7.53%	+42.15%

Apr. 22	CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy	CI
Apr. 12	Transcript : CS Medica A/S, Q4 2023 Earnings Call, Apr 12, 2024

CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2023

November 22, 2023 at 10:43 am EST

CS Medica A/S reported earnings results for the full year ended September 30, 2023. For the full year, the company reported sales was DKK 1.07 million compared to DKK 10.58 million a year ago. Net loss was DKK 14.51 million compared to DKK 10.8 million a year ago.

Latest news about CS MEDICA A/S

CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy	Apr. 22	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Apr 12, 2024	Apr. 12
CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia	Apr. 04	CI
Transcript : CS Medica A/S, 2023 Earnings Call, Feb 21, 2024	Feb. 21
CS MEDICA A/S Partners with New Distributor to Launch CANNASEN into Jordan	Feb. 20	CI
CS Medica Obtains Danish Patent for Wound Healing Gel	Feb. 02	MT
CS Medica Set to Launch Pain Patch, Cosmetic Products in Australia	Jan. 26	MT
CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market	Dec. 27	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Dec 05, 2023	Dec. 05
CS Medica A/S Announces Financial Year Change	Nov. 22	CI
CS Medica A/S Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 22	CI
CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 22	CI
CS Medica's Nasal Protect Gel Secures Second Patent in Denmark	23-10-31	MT
Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products	23-10-12	CI
Danske Bank Extends DKK 1.2 Million Credit Line to CS MEDICA	23-10-10	CI
CS Medica A/S Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-09-13	CI
CS Medica Secures Denmark Patent for Nasal Spray	23-08-30	MT
Transcript : CS Medica A/S, Q3 2023 Earnings Call, Aug 08, 2023	23-08-08
CS MEDICA A/S Announces Establishment of CANNORDIC India Pvt. Ltd. to Expand Presence in India	23-07-14	CI
CS Medica A/S Signs New Own-Label Agreement on Pain Patch	23-06-21	CI
CS Medica Signs Deal for Future Compliance for CE-marked Medical Devices with CBD in EU	23-06-15	MT
CS MEDICA A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body	23-06-15	CI
CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body	23-06-15	CI
CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis	23-05-08	CI
CS Medica A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-04-29	CI

Chart CS MEDICA A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar